ARPI
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
ARPI
Jun 24, 2024, 01:48 |
Insight
Novel PARP inhibitor saruparib in metastatic hormone-sensitive prostate cancer
UroToday shared a post on X: . "The EvoPAR-Prostate 01 Trial:…
Jun 11, 2024, 22:40 |
Blog
Rashid Sayyid: RW study of LuPSMA in VISION-eligible mCRPC patients
Rashid Sayyid, Urologic Oncology Clinical Fellow at University of Toronto, shared a post on X: "RW study of…
Aug 25, 2023, 18:22 |
Insight
Earle Burgess: Which newly diagnosed metastatic castrate-sensitive prostate cancer patients need to add docetaxel chemotherapy to an ADT + ARPI doublet?
Quoting Earle Burgess, Genitourinary Medical Oncologist and Clinical Researcher at Atrium Health, Levine Cancer Institute,…
All:
3
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube